Skip to content

KROS - Keros Therapeutics, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchK

Keros Therapeutics Inc

KROS · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

K

KROSKeros Therapeutics Inc

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $22.55
52-wk low: $9.69
Prev close: $18.67
Mkt cap: $220.1M
Fwd P/E: 48.8x
Beta: 1.01

Smart money

8 funds hold a position and insiders have been net buying.

Real smart money

Funds holding this stock

8 holders

Combined position$66.1M

AQ
AQR
Q2 2026 13F
$10.4M
position
QR
Qube Research
Q2 2026 13F

Earnings

Reported Aug 3, 2026

Earnings came in 16.0% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Forward P/E: 48.78
Market cap: $220M

Valuation

P/S14.66
P/B0.80

Quality

Operating margin-656.0%

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: KROS
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $220.08M
Beta: 1.01

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

P/S

14.7x

P/B

0.8x

Profit margin

+0.0%

Op margin

-656.0%

ROE

-17.2%

$6.5M

position

CI

Citadel

Ken Griffin · Q2 2026 13F

$4.2M

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for KROS

No recent Congress trade
No recent market-voice mention

Earnings per share

-$1.45-16.0%

-$1.25 expected

Next report

What the street expects next

ROE

-17.2%

ROA-11.8%

Growth

Beta1.01